drugset / Trial / NCT06094725
A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
Non-randomizedParallel-groupOpen-labelOther
Summary
The primary objective of this multiple-dose, adaptive design study is to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of relacorilant relative to healthy matched control male and female subjects (Part 1).
Timeline
- Start
- 2020-01-06
- Primary completion
- 2020-12-14
- Completion
- 2020-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relacorilant | Small molecule | 300 mg | Oral |